Officer Files Intent to Sell $1.44M in Olema Pharmaceuticals Stock Amidst Recent Sales
OLMA has more than doubled off its 52-week low of $2.86 on light trading volume (0.3× avg).
Summary
An officer of Olema Pharmaceuticals, David C. Myles, has filed a Form 144 indicating intent to sell 50,000 shares of common stock, valued at approximately $1.44 million, following a pattern of recent sales.
Key Events · Ownership and Investor Activity · OLMA
-
Officer Intent to Sell
David C. Myles, an officer, filed a Form 144 to sell 50,000 shares of common stock.
-
Significant Value
The proposed sale has an approximate market value of $1,443,631.44.
-
Recent Selling History
This filing follows previous sales by Mr. Myles totaling 111,000 shares for gross proceeds of $3,216,925.38 in the past three months.
Analysis · OLMA · Life Sciences
This Form 144 filing indicates that David C. Myles, an officer at Olema Pharmaceuticals, intends to sell a significant block of shares. While the proposed sale represents a small percentage of the company's overall market capitalization, the absolute dollar value of over $1.4 million is notable. Furthermore, this filing follows a pattern of recent sales by Mr. Myles, totaling over $3.2 million in the past three months. Such repeated insider selling, especially from an officer, can be interpreted by investors as a lack of conviction in the company's near-term prospects or a move to diversify holdings.
How filings like this one have moved
In the 30 days to Sep 19, 2026, 29.6% of the 1700 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OLMA was trading at $28.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.86 to $36.26. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.